Research programme: biodefence therapeutics - Evolva/Summit

Drug Profile

Research programme: biodefence therapeutics - Evolva/Summit

Alternative Names: Biodefense therapeutics - Evolva/Summit; EV 009; EV-009-4400; SMT-15000

Latest Information Update: 20 Sep 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Summit plc
  • Developer Evolva Holding SA; Summit plc
  • Class Imino sugars; Small molecules
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bacterial infections; Viral infections

Most Recent Events

  • 07 Sep 2010 Preclinical development in Viral infections and Bacterial infections due to biowarfare is continuing in the UK (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top